Search

The composition of the gut microbiomes in a group of rectal cancer patients reveals distinct signatures by race, ethnicity, and age of onset, with white Hispanics showing significant presence of one specific bacteria, UT Southwestern Medical Center researchers report.

A new initiative funded by The University of Texas System and the state of Texas seeks to improve care for trauma patients.

SLP ASHA Awardees Cory Atkinson, M.A., CCC-SLP April 16, 2026 Laura Toles, Ph.D., CCC-SLP, and Adrianna Shembel, Ph.D., CCC-SLP, were presented with Early Career Contributions in Research awards. Congratulations to three of our UT Southwestern Voice Center speech-language pathologists! The American S…

Editing a gene that prompts a cascade of damage after a heart attack appeared to reverse this inevitable course in mice, leaving their hearts remarkably unharmed, a new study by UT Southwestern scientists showed.

Extended Cricotracheal Resection With Cartilage Grafting for Concurrent Glottic and Subglottic Stenosis Kevin Liang, M.D. Director, UTSW Complex Airway Program April 16, 2026 UT Southwestern established a Complex Airway Program, which includes a multidisciplinary team of otolaryngologists, thoracic s…

Nine scientists and physicians in the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center have been awarded nearly $13 million in grants from the Cancer Prevention and Research Institute of Texas (CPRIT) to support research and prevention efforts on a wide range of cancer issues.

– In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center, a short interfering RNA (siRNA) drug directed to tumor cells, ARO-HIF2, effectively disrupted HIF2α, a key driver of clear cell renal cell carcinoma (ccRCC).

A new approach that targets the cellular machinery that viruses need to reproduce – rather than the virus itself – appears to stem replication of a common childhood pathogen known as respiratory syncytial virus (RSV), UT Southwestern researchers report in a new study.

A first-in-kind immune-modulating drug that arose from decades of basic research at UT Southwestern Medical Center has received approval from the U.S. Food and Drug Administration as a new treatment for myasthenia gravis.

Researchers at UT Southwestern Medical Center studied obstructive sleep apnea in a large group of children and concluded that underweight children with this condition are more likely to have decreased height, tonsillar hypertrophy, and allergic rhinitis.